Pfizer Cuts Outlook, Ends Development of Cholesterol Drug

Pfizer lowered its earnings outlook for the year and said it was ending the development of a drug in the massive cholesterol-treatment sector.

from WSJ.com: US Business http://ift.tt/2e9gctJ
via IFTTT